Actively Recruiting
Evaluating Safety and Preliminary Effects of TQF3250 Capsules in Adults With Type 2 Diabetes and Overweight or Obesity in a Phase 1b Trial
Led by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Updated on 2026-08-28
72
Participants Needed
12
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, pharmacokinetics, and preliminary effects of TQF3250 capsules in adults with type 2 diabetes who are also overweight or obese. This Phase 1b, multi-center, randomized, double-blind, placebo-controlled study plans to enroll 72 participants divided into six dose groups ranging from 4 mg to 40 mg, with a dose-escalation design. Participants will take TQF3250 capsules or a matching placebo orally once daily under fasting conditions for 12 weeks. Each dose group includes 12 subjects, randomized in a 102 ratio to receive either the study drug or placebo. The dosing will follow a titration regimen, gradually increasing to the target dose. During the study, participants will have regular assessments including safety evaluations such as monitoring adverse events and clinical examinations. Pharmacokinetic measurements will be taken at multiple time points before and after dosing, while efficacy will be evaluated through tests like glycated hemoglobin HbA1c, oral glucose tolerance test, body weight, waist circumference, body mass index, fasting plasma glucose, C-peptide, and insulin levels. The total participation lasts about 14 weeks, including follow-up for safety and tolerability.
CONDITIONS
Brief Title
A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity
Research Team
D
Dalong Zhu, Doctor
J
Juan Li, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here